



Contact:

David Waldman or Justyna Gudaszezwska

Crescendo Communications, LLC

Email: mmd@crescendo-ir.com

Tel: +48 693 354 580

Milestone Medical Provides the Update on Commercial Rollout of CompuFlo® Epidural System in the Second Quarter of 2020

ROSELAND, NJ, August 17, 2020 – Milestone Medical Inc. (WAR: MMD) today provided an update on commercial rollout of CompuFlo® Epidural System in the second quarter ended June 30, 2020.

Leonard Osser, Interim Chief Executive Officer of Milestone Medical, commented, “Our primary focus remains commercialization of the CompuFlo® Epidural System, and we are moving ahead aggressively towards this goal. Although we experienced temporary setbacks due to COVID-19 with hospitals on complete lockdown, I am pleased to report our sales and business development pipeline is expanding. We are in late-stage discussions with a number of premier hospitals in the U.S. Moreover, the CathCheck™ technology has resonated well, given its ability to minimize contact between the patient and provider, which is especially important during the COVID-19 pandemic. Importantly, the CompuFlo® Epidural System is fully validated in terms of safety, efficacy and economics. For these reasons, we are as confident as ever that our technology will become the new standard of care.”

“During the second quarter of 2020 the Company’s parent Milestone Scientific Inc. raised gross proceeds of approximately \$19.7 million from the sale of Milestone Scientific common stock and warrants. We believe that the financing from our parent provides us with a substantial runway to help mitigate the risks related to COVID-19, as well as additional resources to accelerate sales and marketing activities around the CompuFlo Epidural System,” concluded Mr. Osser.

About Milestone Medical Inc.

Milestone Medical, Inc. (WAR:MMD) has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic

injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2019. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

###